NYSEHealth CareMedical - Diagnostics & ResearchSnapshot 2026-08-31
Reading IQV? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →Warn: Primary pillar under pressure — Full-year 2026 revenue at $17.15-$17.35 billion: FY26 revenue guidance $17.27B vs $17.15B target.
IQVIA grows revenue about 7% a year, with $17.25 billion guided for 2026. Profit per share is expected near $12.7 in 2026. The company expands its R&D backlog to $32.7 billion, securing future business. It also increased share buyback authorization to $3.2 billion, showing strong capital return.
Revenue growth is slowing, as shown by the recent guidance cut. Competition from Charles River may hurt market share. Debt issuance raises financial risk. Management is volatile, which may affect execution.
The market prices in about 7% revenue growth and values IQVIA roughly 16% below our fair value of $248. Our fair value is 14% above the Street median. We see room for upside if growth and margins hold, but the recent guidance cut and competition risks temper confidence.
Breaks if: Authorization falls below $3.2 billion
Breaks if: EPS falls below $12.55 in FY26
Breaks if: R&D backlog falls below $32.4 billion
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a durable compounder with a focus on long-term growth. The current thesis state is intact, supported by strong recent financial performance and management's commitment to raising guidance.
The market appears to have priced in a neutral valuation, with IQV being relatively cheap compared to its peers. There is a slight expectations gap, indicating that the market may not fully reflect the company's recent positive performance and growth potential.
Fundamentals are likely to remain strong, driven by robust earnings quality and management's successful execution of priorities. However, there is a moderate risk due to potential economic headwinds that could impact performance.
The thesis hinges on management's ability to maintain or raise guidance, as well as the overall health of the healthcare sector. Key forward scenarios include the performance of sector bellwethers and the impact of economic indicators like job reports.
The most important moves since the prior daily snapshot.
Signal changed from 'mild_favorable' to 'favorable'.
Yes, our read has strengthened. The latest earnings beat supports a positive outlook. The company also reaffirmed its full-year 2026 revenue guidance. Additionally, the R&D Solutions backlog and new bookings expanded. There are no new threats to the thesis.
as of 2026-08-31
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
IQVIA aims to expand its R&D Solutions backlog, which was reported at $32.7 billion.
Breaks if: revenue falls below $17.15 billion in FY26
IQVIA is reaffirming its full-year 2026 revenue guidance to be between $17,150 million and $17,350 million.
Over the next 1 to 3 years, IQV's solid operational setup and sector support suggest a favorable outlook. Not investment advice.
